Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord

[Display omitted] Imatinib is a tyrosine kinase inhibitor and is used as a first line drug in the treatment of Philadelphia-chromosome-positive chronic myeloid leukaemia and gastrointestinal stromal tumors. Being tyrosine kinase inhibitor, imatinib modulates the activities of Abelson gene (c-Abl), A...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological research Vol. 143; pp. 86 - 96
Main Authors: Kumar, Manish, Kulshrestha, Ritu, Singh, Nirmal, Jaggi, Amteshwar Singh
Format: Journal Article
Language:English
Published: Netherlands Elsevier Ltd 01.05.2019
Subjects:
Alzheimer’s disease
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Brain
Humans
Imatinib
Imatinib Mesylate - pharmacology
Imatinib Mesylate - therapeutic use
Multiple sclerosis
Nervous System Diseases - drug therapy
Nervous System Diseases - metabolism
Parkinson disease
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Spinal Cord
Spinal cord injury
Stroke
Tyrosine kinase
NF-κβ
Multiple sclerosis
BBB
FLT3
Parkinson disease
Spinal cord injury
LPS
Aβ
Tyrosine kinase
AICD
PDGFR
t-PA
Imatinib
Stroke
AD
MOG
Alzheimer’s disease
c-kit
EAE
c-Abl
MAPK
IL-6
MMP
β-CTF
APC
TNF-α
Lck
ARG
AβPP
GSAP
MPTP
HEK cells
ISSN:1043-6618, 1096-1186, 1096-1186
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Imatinib is a tyrosine kinase inhibitor and is used as a first line drug in the treatment of Philadelphia-chromosome-positive chronic myeloid leukaemia and gastrointestinal stromal tumors. Being tyrosine kinase inhibitor, imatinib modulates the activities of Abelson gene (c-Abl), Abelson related gene (ARG), platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT3), lymphocyte-specific protein (Lck), mitogen activated protein kinase (MAPK), amyloid precursor protein intracellular domain (AICD), α-synuclein and the stem-cell factor receptor (c-kit). Studies have shown the role of imatinib in modulating the pathophysiological state of a number of disorders affecting brain and spinal cord such as Alzheimer’s disease, Parkinson’s disease, stroke, multiple sclerosis and spinal cord injury. The present review discusses the role of imatinib in the above described disorders and the possible mechanisms involved in these diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1043-6618
1096-1186
1096-1186
DOI:10.1016/j.phrs.2019.03.014